105 Rec'd PCT/PTO 12 DEC 1997 08/981087

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ELMORE et al.

Appl. No. (To be assigned; U.S. Natl. Phase of PCT/GB96/01409)

Filed: December 12, 1997 (PCT Filing Date: June 12, 1996)

For: Type F Botulinum Toxin and Use

Thereof

Art Unit: (To be assigned)

Examiner: (To be assigned)

Atty. Docket: 1581.0200000/RWE/BJD

Authorization To Treat A Reply As Incorporating An Extension Of Time Under 37 C.F.R. § 1.136(a)(3)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply. A duplicate copy of this petition is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Robert W. Esmond

Attorney for Applicants

Registration No. 32,893

Date: <u>Vec. 12, 1997</u> 1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600 P:\USERS\BRIAND\1581\0200000\121297.EOT

SKGF Rev. 12/1/97mac